CN110366414A - 用于治疗高血压的组合物 - Google Patents

用于治疗高血压的组合物 Download PDF

Info

Publication number
CN110366414A
CN110366414A CN201780083502.7A CN201780083502A CN110366414A CN 110366414 A CN110366414 A CN 110366414A CN 201780083502 A CN201780083502 A CN 201780083502A CN 110366414 A CN110366414 A CN 110366414A
Authority
CN
China
Prior art keywords
dose
pharmaceutical composition
dosage
composition according
blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780083502.7A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·罗杰斯
克拉拉·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
George Institute for Global Health
Original Assignee
University of Sydney
George Institute for Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sydney, George Institute for Global Health filed Critical University of Sydney
Priority to CN202310591252.5A priority Critical patent/CN116603066A/zh
Publication of CN110366414A publication Critical patent/CN110366414A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780083502.7A 2016-11-15 2017-11-14 用于治疗高血压的组合物 Pending CN110366414A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310591252.5A CN116603066A (zh) 2016-11-15 2017-11-14 用于治疗高血压的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/352,425 2016-11-15
US15/352,425 US10369156B2 (en) 2016-11-15 2016-11-15 Compositions for the treatment of hypertension
PCT/IB2017/001524 WO2018091967A1 (en) 2016-11-15 2017-11-14 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310591252.5A Division CN116603066A (zh) 2016-11-15 2017-11-14 用于治疗高血压的组合物

Publications (1)

Publication Number Publication Date
CN110366414A true CN110366414A (zh) 2019-10-22

Family

ID=62107049

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780083502.7A Pending CN110366414A (zh) 2016-11-15 2017-11-14 用于治疗高血压的组合物
CN202310591252.5A Pending CN116603066A (zh) 2016-11-15 2017-11-14 用于治疗高血压的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310591252.5A Pending CN116603066A (zh) 2016-11-15 2017-11-14 用于治疗高血压的组合物

Country Status (8)

Country Link
US (2) US10369156B2 (https=)
EP (2) EP4574136A3 (https=)
JP (3) JP2019536816A (https=)
CN (2) CN110366414A (https=)
AU (3) AU2017359607A1 (https=)
CA (1) CA3043835A1 (https=)
TW (1) TWI799397B (https=)
WO (1) WO2018091967A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
SI4101454T1 (sl) 2017-01-25 2024-10-30 The George Institute for Global Health Sestavki za uporabo pri zdravljenju hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2019241590A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
AU2019309329B2 (en) * 2018-07-26 2025-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
JP2021536443A (ja) * 2018-08-25 2021-12-27 シーアールディー ファーマシューティカルズ インコーポレイティド 高血圧治療をサーカディアンリズムと同期させる
KR102900997B1 (ko) * 2019-12-11 2025-12-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
EP4649946A1 (en) * 2024-05-16 2025-11-19 Alba Research S.r.l. Compositions for treating arterial hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146900A2 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
ATE326240T2 (de) 2000-04-10 2006-06-15 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20050187262A1 (en) 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
US20070191438A1 (en) * 2004-04-06 2007-08-16 Rohrer Susan P Methods for the treatment of hypertension
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
CN101450211A (zh) 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
WO2011149438A1 (en) 2010-05-28 2011-12-01 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
US10918612B2 (en) 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
CN106310278A (zh) 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
SI4101454T1 (sl) 2017-01-25 2024-10-30 The George Institute for Global Health Sestavki za uporabo pri zdravljenju hipertenzije

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146900A2 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
STEVEN FISHBANE等: "Iron deficiency in non-dialysis chronic kidney disease", 《KIDNEY INTERNATIONAL》 *
VISHAL R. TANDON等: "Antihypertensive drug prescription patterns, rationality,", 《JOURNAL OF MID-LIFE HEALTH》 *
申献玲等: "复方血压安缓释片的制备及质量控制", 《中国药房》 *
郭艳歌等: "厄贝沙坦、氢氯噻嗪、氨氯地平联合美托洛尔治疗难治性高血压效果分析", 《中国临床新医学》 *
霍刚等: "辛伐他汀对中老年高血压患者踝臂指数的影响", 《中国药房》 *

Also Published As

Publication number Publication date
EP3541379A4 (en) 2020-05-27
JP2019536816A (ja) 2019-12-19
JP2023095844A (ja) 2023-07-06
AU2023258387B2 (en) 2025-05-29
JP2025102796A (ja) 2025-07-08
TW201828988A (zh) 2018-08-16
US10369156B2 (en) 2019-08-06
EP4574136A2 (en) 2025-06-25
WO2018091967A1 (en) 2018-05-24
AU2025210908A1 (en) 2025-08-21
EP3541379A1 (en) 2019-09-25
AU2017359607A1 (en) 2019-06-06
EP4574136A3 (en) 2025-09-17
BR112019009859A2 (pt) 2019-08-20
US20180133227A1 (en) 2018-05-17
TWI799397B (zh) 2023-04-21
US20190314383A1 (en) 2019-10-17
AU2023258387A1 (en) 2023-11-23
CA3043835A1 (en) 2018-05-24
CN116603066A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
CN110366414A (zh) 用于治疗高血压的组合物
JP2025010535A (ja) 高血圧症の処置のための組成物
JP2024099574A (ja) 高血圧症の処置のための組成物
HK40116862A (zh) 用於治疗高血压的组合物
HK40092202A (zh) 用於治疗高血压的组合物
RU2828226C2 (ru) Композиции для лечения гипертензии
BR112019009859B1 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma
BR122024023236A2 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma
HK40052456A (en) Compositions for the treatment of hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191022